FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089756110> ?p ?o ?g. }

• W2089756110 endingPage "4782" @default.
• W2089756110 startingPage "4774" @default.
• W2089756110 abstract "Abstract Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a novel treatment modality in oncology. Preclinical findings suggest that long-term clinical outcomes may improve with blockade of additional proangiogenic receptor tyrosine kinases: platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR). BIBF 1120 is an indolinone derivative potently blocking VEGF receptor (VEGFR), PDGFR and FGFR kinase activity in enzymatic assays (IC50, 20–100 nmol/L). BIBF 1120 inhibits mitogen-activated protein kinase and Akt signaling pathways in three cell types contributing to angiogenesis, endothelial cells, pericytes, and smooth muscle cells, resulting in inhibition of cell proliferation (EC50, 10–80 nmol/L) and apoptosis. In all tumor models tested thus far, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model, BIBF 1120 is highly active at well-tolerated doses (25–100 mg/kg daily p.o.), as measured by magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and inducing profound growth inhibition. A distinct pharmacodynamic feature of BIBF 1120 in cell culture is sustained pathway inhibition (up to 32 hours after 1-hour treatment), suggesting slow receptor off-kinetics. Although BIBF 1120 is rapidly metabolized in vivo by methylester cleavage, resulting in a short mean residence time, once daily oral dosing is fully efficacious in xenograft models. These distinctive pharmacokinetic and pharmacodynamic properties may help explain clinical observations with BIBF 1120, currently entering phase III clinical development. [Cancer Res 2008;68(12):4774–82]" @default.
• W2089756110 created "2016-06-24" @default.
• W2089756110 creator A5011186689 @default.
• W2089756110 creator A5013048035 @default.
• W2089756110 creator A5033883833 @default.
• W2089756110 creator A5049002384 @default.
• W2089756110 creator A5055761451 @default.
• W2089756110 creator A5060157021 @default.
• W2089756110 creator A5065339919 @default.
• W2089756110 creator A5071971790 @default.
• W2089756110 creator A5074720413 @default.
• W2089756110 creator A5075113397 @default.
• W2089756110 creator A5075131045 @default.
• W2089756110 creator A5080417158 @default.
• W2089756110 date "2008-06-15" @default.
• W2089756110 modified "2023-10-17" @default.
• W2089756110 title "BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy" @default.
• W2089756110 cites W1965380392 @default.
• W2089756110 cites W1969328947 @default.
• W2089756110 cites W1970053353 @default.
• W2089756110 cites W1973918329 @default.
• W2089756110 cites W1977013517 @default.
• W2089756110 cites W1977030165 @default.
• W2089756110 cites W1977999028 @default.
• W2089756110 cites W1978139448 @default.
• W2089756110 cites W1982246723 @default.
• W2089756110 cites W1982912692 @default.
• W2089756110 cites W2015809080 @default.
• W2089756110 cites W2021753139 @default.
• W2089756110 cites W2025194878 @default.
• W2089756110 cites W2029108033 @default.
• W2089756110 cites W2042098439 @default.
• W2089756110 cites W2053500182 @default.
• W2089756110 cites W2065550467 @default.
• W2089756110 cites W2094935740 @default.
• W2089756110 cites W2097373408 @default.
• W2089756110 cites W2099279915 @default.
• W2089756110 cites W2110066617 @default.
• W2089756110 cites W2115141581 @default.
• W2089756110 cites W2115390024 @default.
• W2089756110 cites W2120220319 @default.
• W2089756110 cites W2121330976 @default.
• W2089756110 cites W2125212831 @default.
• W2089756110 cites W2131393213 @default.
• W2089756110 cites W2140765540 @default.
• W2089756110 cites W2143296044 @default.
• W2089756110 cites W2144081223 @default.
• W2089756110 cites W2147176626 @default.
• W2089756110 cites W2149806683 @default.
• W2089756110 cites W2152251876 @default.
• W2089756110 cites W2162352067 @default.
• W2089756110 cites W2170499574 @default.
• W2089756110 cites W2246054985 @default.
• W2089756110 cites W4241334709 @default.
• W2089756110 cites W4244491773 @default.
• W2089756110 cites W4253705647 @default.
• W2089756110 cites W4254239453 @default.
• W2089756110 cites W89844829 @default.
• W2089756110 doi "https://doi.org/10.1158/0008-5472.can-07-6307" @default.
• W2089756110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18559524" @default.
• W2089756110 hasPublicationYear "2008" @default.
• W2089756110 type Work @default.
• W2089756110 sameAs 2089756110 @default.
• W2089756110 citedByCount "864" @default.
• W2089756110 countsByYear W20897561102012 @default.
• W2089756110 countsByYear W20897561102013 @default.
• W2089756110 countsByYear W20897561102014 @default.
• W2089756110 countsByYear W20897561102015 @default.
• W2089756110 countsByYear W20897561102016 @default.
• W2089756110 countsByYear W20897561102017 @default.
• W2089756110 countsByYear W20897561102018 @default.
• W2089756110 countsByYear W20897561102019 @default.
• W2089756110 countsByYear W20897561102020 @default.
• W2089756110 countsByYear W20897561102021 @default.
• W2089756110 countsByYear W20897561102022 @default.
• W2089756110 countsByYear W20897561102023 @default.
• W2089756110 crossrefType "journal-article" @default.
• W2089756110 hasAuthorship W2089756110A5011186689 @default.
• W2089756110 hasAuthorship W2089756110A5013048035 @default.
• W2089756110 hasAuthorship W2089756110A5033883833 @default.
• W2089756110 hasAuthorship W2089756110A5049002384 @default.
• W2089756110 hasAuthorship W2089756110A5055761451 @default.
• W2089756110 hasAuthorship W2089756110A5060157021 @default.
• W2089756110 hasAuthorship W2089756110A5065339919 @default.
• W2089756110 hasAuthorship W2089756110A5071971790 @default.
• W2089756110 hasAuthorship W2089756110A5074720413 @default.
• W2089756110 hasAuthorship W2089756110A5075113397 @default.
• W2089756110 hasAuthorship W2089756110A5075131045 @default.
• W2089756110 hasAuthorship W2089756110A5080417158 @default.
• W2089756110 hasBestOaLocation W20897561101 @default.
• W2089756110 hasConcept C101544691 @default.
• W2089756110 hasConcept C121608353 @default.
• W2089756110 hasConcept C126322002 @default.
• W2089756110 hasConcept C167734588 @default.
• W2089756110 hasConcept C170493617 @default.
• W2089756110 hasConcept C180361614 @default.
• W2089756110 hasConcept C185592680 @default.
• W2089756110 hasConcept C2775960820 @default.

• next